Arcellx

Last updated: April 15, 2024

David Hilbert - President & CEO
David Hilbert - President & CEO
Country: USA | Funding: $622M (+)

Website: http://www.arcellx.com/

Arcellx develops intelligent and adaptive cell therapies to treat the complexity of human disease. It intends to provide cancer patients with first-in-class adaptive immune cell therapies that are readily silenced, activated, and reprogrammed throughout the course of disease.